Hepatitis C in childhood.
The approach of a pediatric hepatologist in managing children with hepatitis C virus (HCV) differs from adult practice, because the pediatric hepatologist is dealing with the beginning of a chronic illness in which long-term outcomes will not occur for 20 or 40 years, and it is not possible to predict in the early stages of the infection which patients have a more sinister prognosis. The prevalence of chronic HCV in children is low, but varies between different countries in the Asia-Pacific region. In most countries, screening of blood products for HCV has virtually eliminated the risk of post-transfusion HCV, so that in Australia children aged less than 11 years will not have acquired HCV from blood transfusion or extracorporeal membrane oxygenation. The risk of perinatal transmission of this virus is only about 6%, but this remains virtually the only source of HCV transmission for children in most countries. While available data are limited, mild histological changes are present in the majority of children with hepatitis C, and cirrhosis is rare. Unfortunately, long-term natural history studies of the course of HCV infection in children have not been reported. Individual decisions on antiviral treatment are more difficult in childhood, not because the treatment is any less effective or because of the severity of side-effects (which tend to be less severe than for adults), but because the long-term outcome of infection is unclear. At present, treatment should be confined to those with significant hepatic fibrosis and continued moderate to severe necroinflammatory change. Measures to prevent HCV infection in childhood center on whether, as recently suggested, elective cesarean section may reduce the risk of transmission. Despite the presence of HCV-RNA in some breast milk samples, there is no evidence that breast-feeding confers any risk of HCV infection.
Hardikar
Winita
W
Paediatric Gastroenterology and Hepatology, Royal Children's Hospital, Flemington Road, Parkville, Melbourne, Victoria 3052, Australia. hardikaw@cryptic.rch.unimelb.edu.au
D000998:Antiviral Agents / Q000627:therapeutic use; D002675:Child, Preschool; D019411:Clinical Laboratory Techniques; D006526:Hepatitis C / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy* / Q000635:transmission; D006801:Humans; D011315:Preventive Medicine / Q000379:methods; D011788:Quality of Life; D065227:Transfusion Reaction
D000998:Antiviral Agents